Document:

exv10w3

 

Exhibit 10.3

AMENDMENT TO EMPLOYMENT AGREEMENT

This Amendment to Employment Agreement is dated as of May 1, 2008 (the “Amendment”) by and between
Perrigo Company (the “Parent”), Perrigo Israel Pharmaceuticals, Ltd., formerly Agis Industries
(1983) Ltd. (the “Company”), and Refael Lebel (the “Executive”).

     WHEREAS the Parent, Company and Executive are parties to a certain Employment Agreement dated
as of November 14, 2004 (the “Employment Agreement”) which provides, among other things, that the
Company agrees to employ the Executive subject to certain terms and conditions contained in the
Employment Agreement; and

     WHEREAS the Parent, Company and Executive wish to amend the Employment Agreement as set forth
herein.

     NOW THEREFORE, in consideration of the mutual covenants and agreements set forth below and for
other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the
parties agree as follows:

     1. Amendment.

	 	a.	 	Section 1(a) of the Employment Agreement is deleted in its
entirety and replaced by the following:
	 
	 	 	 	“Subject to the terms of this Agreement, the Company agrees to employ the
Executive in the position of President during the Agreement Term (as defined
in Section 1(i) below), and the Executive agrees to remain in the employ of
the Company during the Agreement Term. The Parent agrees to appoint the
Executive and the Executive agrees to serve, as an Executive Vice President
and as a member of the Parent’s Executive Committee (“Executive Committee”).”
	 
	 	b.	 	Section 1(c) of the Employment Agreement is deleted in its
entirety and replaced by the following:
	 
	 	 	 	“The Executive shall report to the Parent’s Chief Executive Officer and shall
perform such duties as may be assigned to him by the Chief Executive Officer.
Such duties shall include daily leadership and coordination of the Parent’s
and Company’s (1) generic pharmaceuticals business outside North America, (2)
global API business, (3) the Israel-based Consumer Products and Pharmaceutical
and Diagnostics businesses, and (4) the Israel-based pharmaceuticals’
operations, including monitoring achievement of operations and financial
results and developing growth strategies to achieve ongoing

1

 

	 	 	 	objectives. Current Company staff (except those in the United States), shall
directly report to the Executive. The Parent may make changes to the
Executive’s position, title, reporting line, authority and responsibilities,
provided that the totality of the Executive’s position, title, reporting line,
authority and responsibilities as comparable to those typically attributable
to members of the Executive Committee.”
	 
	 	c.	 	The first sentence of Section 1(i) is deleted in its entirety
and replaced by the following:

	 	 	 	“This Agreement shall govern the terms and conditions of the
Executive’s employment and any termination thereof from the Effective
Date until March 17, 2011 (the “Agreement Term”).”

	 	d.	 	Section 2(a) of the Employment Agreement is deleted in its
entirety and replaced by the following:
	 
	 	 	 	“Base Salary. The Executive shall receive base salary at an annual rate of
1.670.000 NIS, payable in substantially equal monthly or more frequent
installments (the “Salary”). Commencing on or around October 2008, the
Executive’s Salary shall be reviewed for increase at least annually by the
Chief Executive Officer, the Board or the Compensation Committee of the Board
pursuant to the normal review process for members of the Executive Committee.
Any increase in Salary shall not serve to limit or reduce any other obligation
to the Executive under this Agreement.”
	 
	 	e.	 	The third sentence of Section 2(b) of the Employment
Agreement is deleted in its entirety and replaced by the following:
	 
	 	 	 	“The MIB shall provide the Executive with a target bonus opportunity of 60% of
annual salary for each fiscal year of the Parent.”
	 
	 	f.	 	Section 3(g)(i) is deleted in its entirety and replaced by
the following:

	 	 	 	“. . . (i) any breach or violation of Section 1(c) or the Parent or
Company requiring the Executive to relocate his principal place of
employment outside the State of Israel, . . .”

	 	g.	 	Section 7 of the Employment Agreement is deleted in its
entirety.

2

 

	 	2.	 	Confidentiality and Noncompetition.
	 
	 	 	 	In consideration for the payments and benefits contemplated by Section 4 of the
Employment Agreement, the Executive acknowledges and agrees that simultaneous with the
execution of this Amendment, he will be required to execute and comply with the
Noncompetition and Nondisclosure Agreement in the form attached to this Amendment as
Exhibit A. This Noncompetition and Nondisclosure Agreement supersedes and replaces the
previous Noncompetition and Nondisclosure Agreement entered into on November 14, 2004
by and between the Parent and Executive.
	 
	 	3.	 	Effect of Amendment.
	 
	 	 	 	Except to the extent expressly amended hereby, the Employment Agreement shall remain in
full force and effect in all respects.
	 
	 	4.	 	Applicable Law.
	 
	 	 	 	This Amendment shall be governed by and construed and enforced in accordance with the
internal laws of the State of Israel without regard to principles of conflict of laws.
Any proceeding related to or arising out of this Amendment shall be commenced,
prosecuted or continued in Israel. Notwithstanding the foregoing, any controversy
relating to provisions of Section 2(b) and 2(c) of the Employment Agreement shall be
governed by the laws of the jurisdiction set forth in the applicable award document.
	 
	 	5.	 	Counterparts.
	 
	 	 	 	This amendment may be executed in one or more counterparts (including counterparts
executed and delivered by facsimile, which shall be as counterparts executed and
delivered manually) all of which shall be considered one in the same agreement and
shall become effective when one or more counterparts have been signed by each of the
parties and delivered to the other parties as being understood that all parties do not
sign the same counterpart.

3

 

IN WITNESS WHEREOF, this Amendment has been duly executed by the parties as of the day and year
first written above.

PERRIGO COMPANY

	 	 	 	 	 
	By:

	 	/s/ Joseph C. Papa
	 	 
	 

	 	 	 	 
	Its:

	 	President and Chief Executive Officer	 	 

EXECUTIVE

	 	 	 	 	 
	By:

	 	/s/ Refael Lebel
 

	 	 

PERRIGO ISRAEL PHARMACEUTICALS LTD.

	 	 	 	 	 
	By:
	 	/s/ Judy L. Brown	 	 
	 

	 	 	 	 
	Its:
	 	Executive Vice President and

Chief Financial Officer	 	 

4

 

Exhibit A

NONCOMPETITION AND NONDISCLOSURE AGREEMENT

     THIS NONCOMPETITION AND NONDISCLOSURE AGREEMENT (the “Agreement”) is entered into as of May 1,
2008 by and between Perrigo Company, a Michigan corporation, for and in behalf of itself and each
of its subsidiary and affiliated companies, including Perrigo Israel Pharmaceuticals Ltd. (formerly
Agis Industries (1983) Ltd.) (collectively referred to as “Perrigo”) and Refael Lebel (the
“Executive”).

     WHEREAS Executive has entered into an employment agreement with Perrigo dated as of November
14, 2004 and amended as of May 1, 2008 (the “Employment Agreement”) pursuant to which Executive
became a key employee of Perrigo. In connection with such employment, Executive has obtained or
will obtain access to sensitive information regarding Perrigo’s Business (as defined below) and
Perrigo’s customers. The parties agree that improper disclosure or use of that information will
cause serious and irreparable harm to Perrigo.

     WHEREAS Perrigo’s special competence in its various fields of endeavor is the secret of its
growth and provides the source of both career opportunities and security for employees throughout
Perrigo. Such growth depends to a significant degree on Perrigo’s confidential, proprietary
information. This is information that is not generally known to the public and includes more and
better information than our competitors have about Perrigo’s Business. For purposes of this
Agreement “Perrigo’s Business” shall mean, without limitation, the research, development,
production, marketing, manufacture, preparation, handling, treatment, storage, sale, distribution,
shipment and use of pharmaceutical products (including prescription, generic, brand, store brand,
value brand, over-the-counter (OTC) and nutritional products), active pharmaceutical ingredients, or any
other products that Perrigo or one of its affiliates is marketing or actively planning to market
during the Agreement Term (as that term is defined in the Employment Agreement). To obtain such
information and use it successfully, Perrigo spends considerable sums of money in product
development, the development of marketing methods, training its employees, and service to its
customers.

     NOW THEREFORE, in consideration of Perrigo’s agreement to employ Executive and provide the
compensation and benefits as set forth in the Employment Agreement and for other good and valuable
consideration, the receipt of which is acknowledged, the parties agree as follows:

     1. Restriction on Competing Activities.

     (a) Subject to Section 1(b) and (c) below, during the Agreement Term (as defined in the
Employment Agreement) and ending on the first anniversary of the Executive’s Date of Termination
(as defined in the Employment Agreement) (the “Non-Competition Period”), Executive will not,
directly or indirectly, alone or as a partner, officer, director, owner, employee, or consultant of
any business or other entity, be engaged in any business or other enterprise that competes,
directly or indirectly, in any way with the Perrigo Business. In addition to its plain meaning and
understanding, “compete in any

5

 

Exhibit A

way with the Perrigo Business” shall also specifically include being employed by or providing
consulting or other substantial services to any company that in any way sells, manufactures,
distributes or develops store brand or value brand OTC drug or nutritional products, topical
generic prescription pharmaceutical products, active pharmaceutical ingredients or any other
product that Perrigo or one of its affiliates is marketing or actively planning to market during
the Noncompetition period, as used in this Agreement, “store brand and value brand products” means
those products that are supplied by a manufacturer or marketer through channels of distribution
(including but not limited to, wholesalers, distributors and retailers) that bear either (i) a
label or brand name that is used exclusively by the wholesaler, distributor or retailer, or (ii) a
label or brand name that is not regularly advertised by national broadcast, print, direct mail or
other media for the purpose of establishing brand name recognition of the manufacturer, marketer
and/or distributor with the general public. Executive also agrees that during the Non-Competition
Period, he will not, directly or indirectly, either for himself or any other person, solicit or
induce, or attempt to solicit or induce, any individual who is an employee, independent contractor,
supplier, or customer of Perrigo to terminate his, her, or its business relationship with the
company or in any way interfere with or disrupt the company’s relationship with any of its
employees, independent contractors, suppliers, or customers.

     (b) In the event Perrigo provides timely notice of non-renewal to Executive pursuant to
Section 1(i) of the Employment Agreement, the restrictions on competing activities found in Section
1(a) above will expire on the last day that Executive is employed by Perrigo.

     (c) In
the event Executive provides timely notice of non-renewal to Perrigo
pursuant to Section 1 (i)
of the Employment Agreement, during the Non-Competition Period, Executive shall not be precluded
from being employed by or serving as a consultant to any business or other enterprise that competes
in any way with the Perrigo Business, but only to the extent that such employment or consulting
services do not relate, directly or indirectly, to an OTC drug or nutritional product, topical
generic prescription pharmaceutical product, active pharmaceutical ingredient or any other product
that Perrigo or one of its affiliates is marketing or actively planning to market during the
Agreement Term and ending on the first anniversary of the Executive’s date of termination.

     2. Nondisclosure. Executive will not during or at any time after the termination of
employment with Perrigo use, divulge, or convey to others any secret or confidential information,
knowledge or data of Perrigo or that of third parties obtained by Executive during the period of
employment with Perrigo. Such secret or confidential information, knowledge or data includes, but
is not limited to, secret or confidential matters:

     (a) of a technical nature such as, but not limited to, methods, know-how, formulas,
compositions, processes, discoveries, machines, inventions, computer programs and similar items or
research projects,

6

 

Exhibit A

     (b) of a business nature such as, but not limited to, information about costs, purchasing,
profits, marketing, sales or lists of customers, and

     (c) pertaining to future developments such as, but not limited to, research and development or
future marketing or merchandising.

     3. Inventions and Patents. Executive acknowledges that all inventions, innovations,
improvements, developments, methods, designs, analyses, drawings, reports and all similar or
related information (whether or not patentable) which relate to Perrigo’s actual or anticipated
business, research and development or existing or future products or services and which are
conceived, developed or made by Executive while providing services to the Perrigo (“Work
Product”) belong to Perrigo. Executive shall promptly disclose such Work Product to Perrigo’s
General Counsel and perform all actions requested by Perrigo (whether during or after Executive’s
period of employment) to establish and confirm such ownership (including, without limitation,
executing assignments, consents, powers of attorney and other instruments).

     4. Return of Company Property. Upon termination of employment with Perrigo, or at any
other time at Perrigo’s request, Executive agrees:

     (a) To deliver promptly to Perrigo all manuals, letters, notes, papers, books, reports,
sketches, computer data or disks, files and programs, price lists, customer files, memoranda,
contracts and agreements, business and marketing plans, product formulations, manufacturing
processes, procedures and methods (including equipment specifications and drawings), vendor lists,
vendor files, customer lists, stored or recorded documents, and all other materials and copies
thereof relating in any way to the Perrigo Business and in any way obtained by Executive during the
period of employment with Perrigo which are in Executive’s possession or under his control.
Executive further agrees that he will not make or retain any copies of any of the foregoing and
will so represent to Perrigo upon termination of employment.

     (b) To confirm to Perrigo that all of Perrigo’s computer records, files and programs have
first been turned over to Perrigo and then deleted or erased from all computer equipment owned,
leased or used by Executive.

     (c) To return to Perrigo all personal property provided for Executive’s use during his
employment with Perrigo including, but not limited to, automobiles, computers and related
equipment, telephones, credit cards, security cards and identifications, keys and tools.

     5. Remedies. Executive acknowledges and agrees that monetary damages for his breach of
any provision of this Agreement would be an inadequate remedy and that would not have an adequate
remedy at law for such breach. Accordingly, Executive agrees that, in addition to all other rights
and remedies available to the company to enforce its rights pursuant to this Agreement, Perrigo
shall, without the necessity of

7

 

Exhibit A

proving irreparable harm or of posting a bond, be entitled to such equitable relief from any court
with proper jurisdiction, including, but not limited to, an injunction, a temporary restraining
order, or an order for specific performance, as may be necessary to enforce or prevent a violation
(whether anticipatory, continuing, or future) of any provision of this Agreement. If Executive
breaches any provision of this Agreement, he shall pay all expenses, including court costs and
actual attorney fees, incurred by Perrigo in enforcing such provision.

     6. Enforceability. The unenforceability of any provision or portion of any provision
of this Agreement shall not affect the enforceability of the remaining provisions or the remainder
of any provision of this Agreement. If at any time a court determines that any restrictive covenant
contained in this Agreement is unreasonable, the parties agree that the maximum restriction
permitted by law shall be substituted for the stated restriction and that such substitution shall
govern this Agreement as if originally part of this Agreement.

     7. Binding Effect. This Agreement and the rights and obligations of Perrigo hereunder
shall inure to the benefit of and be binding upon Perrigo and its successors and assigns.

     8. Entire Agreement Modifications. This Agreement contains the entire agreement
between the parties with respect to its subject matter and supersedes all other agreements, whether
oral or written, between the parties regarding such subject matter. This Agreement may be modified
or terminated only through a written instrument signed by each of the parties.

     9. Waiver. The waiver by either party of the enforcement or the breach of any
provision of this Agreement shall not operate or be construed as a subsequent or continuing waiver
of the enforcement or the breach of any provision. The failure by either party to insist upon
strict compliance of any provision of this Agreement shall not be deemed a waiver of such
provision. No waiver shall be valid unless in writing and signed by the party giving the waiver.

     10. Governing Law. This Agreement shall be governed by laws of Israel, provided,
however, that with respect to acts that occur in the United States (“US Based Conduct”) that would
constitute a breach of this Agreement and any disputes relating to such acts shall be governed by
and construed and enforced in accordance with the internal laws of the State of Michigan without
regard to principals of conflict of laws with respect to any acts occurring in the United States.
Any proceeding related to or arising out of this Agreement relating to US Based Conduct shall be
commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand
Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and
in any appellate court thereof. Executive accepts, with respect to US Based Conduct, generally and
unconditionally, the exclusive jurisdiction of the aforesaid courts and waives any defense of
forum non conveniens, and irrevocably agrees to be bound by any final and
nonappealable judgment rendered thereby in connection with this

8

 

Exhibit A

Agreement. Executive further irrevocably consents, with respect to US Based Conduct, to the
service of process out of any of the aforementioned courts in any such action or proceeding by the
mailing of copies thereof via overnight courier, such service to become effective fourteen calendar
days after such mailing.

IN WITNESS WHEREOF, this Agreement been duly executed by the parties as of the day and year first
written above.

PERRIGO COMPANY

	 	 	 	 	 
	By:

	 	/s/ Joseph C. Papa
 

	 	 
	Its:

	 	President and Chief Executive Officer	 	 

EXECUTIVE

	 	 	 	 	 
	By:

	 	/s/ Refael Lebel
 

	 	 

PERRIGO ISRAEL PHARMACEUTICALS LTD.

	 	 	 	 	 
	By:
	 	/s/ Judy L. Brown	 	 
	 

	 	 	 	 
	Its:
	 	Executive Vice President and

Chief Financial Officer	 	 

9exv10w4

 

Exhibit 10.4

NONCOMPETITION AND NONDISCLOSURE AGREEMENT

     THIS NONCOMPETITION AND NONDISCLOSURE AGREEMENT (the “Agreement”) is entered into as of May 1,
2008 by and between Perrigo Company, a Michigan corporation, for and in behalf of itself and each
of its subsidiary and affiliated companies, including Perrigo Israel Pharmaceuticals Ltd. (formerly
Agis Industries (1983) Ltd.) (collectively referred to as “Perrigo”) and Refael Lebel (the
“Executive”).

     WHEREAS Executive has entered into an employment agreement with Perrigo dated as of November
14, 2004 and amended as of May 1, 2008 (the “Employment Agreement”) pursuant to which Executive
became a key employee of Perrigo. In connection with such employment, Executive has obtained or
will obtain access to sensitive information regarding Perrigo’s Business (as defined below) and
Perrigo’s customers. The parties agree that improper disclosure or use of that information will
cause serious and irreparable harm to Perrigo.

     WHEREAS Perrigo’s special competence in its various fields of endeavor is the secret of its
growth and provides the source of both career opportunities and security for employees throughout
Perrigo. Such growth depends to a significant degree on Perrigo’s confidential, proprietary
information. This is information that is not generally known to the public and includes more and
better information than our competitors have about Perrigo’s Business. For purposes of this
Agreement “Perrigo’s Business” shall mean, without limitation, the research, development,
production, marketing, manufacture, preparation, handling, treatment, storage, sale, distribution,
shipment and use of pharmaceutical products (including prescription, generic, brand, store brand,
value brand, over-the-counter (OTC) and nutritional products), active pharmaceutical ingredients, or any
other products that Perrigo or one of its affiliates is marketing or actively planning to market
during the Agreement Term (as that term is defined in the Employment Agreement). To obtain such
information and use it successfully, Perrigo spends considerable sums of money in product
development, the development of marketing methods, training its employees, and service to its
customers.

     NOW THEREFORE, in consideration of Perrigo’s agreement to employ Executive and provide the
compensation and benefits as set forth in the Employment Agreement and for other good and valuable
consideration, the receipt of which is acknowledged, the parties agree as follows:

     1. Restriction on Competing Activities.

     (a) Subject to Section 1(b) and (c) below, during the Agreement Term (as defined in the
Employment Agreement) and ending on the first anniversary of the Executive’s Date of Termination
(as defined in the Employment Agreement) (the “Non-Competition Period”), Executive will not,
directly or indirectly, alone or as a partner, officer, director, owner, employee, or consultant of
any business or other entity, be engaged in any

 

 

business or other enterprise that competes, directly or indirectly, in any way with the
Perrigo Business. In addition to its plain meaning and understanding, “compete in any way with the
Perrigo Business” shall also specifically include being employed by or providing consulting or
other substantial services to any company that in any way sells, manufactures, distributes or
develops store brand or value brand OTC drug or nutritional products, topical generic prescription
pharmaceutical products, active pharmaceutical ingredients or any other product that Perrigo or one
of its affiliates is marketing or actively planning to market during the Noncompetition period, as
used in this Agreement, “store brand and value brand products” means those products that are
supplied by a manufacturer or marketer through channels of distribution (including but not limited
to, wholesalers, distributors and retailers) that bear either (i) a label or brand name that is
used exclusively by the wholesaler, distributor or retailer, or (ii) a label or brand name that is
not regularly advertised by national broadcast, print, direct mail or other media for the purpose
of establishing brand name recognition of the manufacturer, marketer and/or distributor with the
general public. Executive also agrees that during the Non-Competition Period, he will not,
directly or indirectly, either for himself or any other person, solicit or induce, or attempt to
solicit or induce, any individual who is an employee, independent contractor, supplier, or customer
of Perrigo to terminate his, her, or its business relationship with the company or in any way
interfere with or disrupt the company’s relationship with any of its employees, independent
contractors, suppliers, or customers.

     (b) In the event Perrigo provides timely notice of non-renewal to Executive pursuant to
Section 1(i) of the Employment Agreement, the restrictions on competing activities found in Section
1(a) above will expire on the last day that Executive is employed by Perrigo.

     (c) In
the event Executive provides timely notice of non-renewal to Perrigo
pursuant to Section 1 (i)
of the Employment Agreement, during the Non-Competition Period, Executive shall not be precluded
from being employed by or serving as a consultant to any business or other enterprise that competes
in any way with the Perrigo Business, but only to the extent that such employment or consulting
services do not relate, directly or indirectly, to an OTC drug or nutritional product, topical
generic prescription pharmaceutical product, active pharmaceutical ingredient or any other product
that Perrigo or one of its affiliates is marketing or actively planning to market during the
Agreement Term and ending on the first anniversary of the Executive’s date of termination.

     2. Nondisclosure. Executive will not during or at any time after the termination of
employment with Perrigo use, divulge, or convey to others any secret or confidential information,
knowledge or data of Perrigo or that of third parties obtained by Executive during the period of
employment with Perrigo. Such secret or confidential information, knowledge or data includes, but
is not limited to, secret or confidential matters:

     (a) of a technical nature such as, but not limited to, methods, know-how, formulas,
compositions, processes, discoveries, machines, inventions, computer programs
and similar items or research projects,

 

 

     (b) of a business nature such as, but not limited to, information about costs, purchasing,
profits, marketing, sales or lists of customers, and

     (c) pertaining to future developments such as, but not limited to, research and development or
future marketing or merchandising.

     3. Inventions and Patents. Executive acknowledges that all inventions, innovations,
improvements, developments, methods, designs, analyses, drawings, reports and all similar or
related information (whether or not patentable) which relate to Perrigo’s actual or anticipated
business, research and development or existing or future products or services and which are
conceived, developed or made by Executive while providing services to the Perrigo (“Work
Product”) belong to Perrigo. Executive shall promptly disclose such Work Product to Perrigo’s
General Counsel and perform all actions requested by Perrigo (whether during or after Executive’s
period of employment) to establish and confirm such ownership (including, without limitation,
executing assignments, consents, powers of attorney and other instruments).

     4. Return of Company Property. Upon termination of employment with Perrigo, or at any
other time at Perrigo’s request, Executive agrees:

     (a) To deliver promptly to Perrigo all manuals, letters, notes, papers, books, reports,
sketches, computer data or disks, files and programs, price lists, customer files, memoranda,
contracts and agreements, business and marketing plans, product formulations, manufacturing
processes, procedures and methods (including equipment specifications and drawings), vendor lists,
vendor files, customer lists, stored or recorded documents, and all other materials and copies
thereof relating in any way to the Perrigo Business and in any way obtained by Executive during the
period of employment with Perrigo which are in Executive’s possession or under his control.
Executive further agrees that he will not make or retain any copies of any of the foregoing and
will so represent to Perrigo upon termination of employment.

     (b) To confirm to Perrigo that all of Perrigo’s computer records, files and programs have
first been turned over to Perrigo and then deleted or erased from all computer equipment owned,
leased or used by Executive.

     (c) To return to Perrigo all personal property provided for Executive’s use during his
employment with Perrigo including, but not limited to, automobiles, computers and related
equipment, telephones, credit cards, security cards and identifications, keys and tools.

     5. Remedies. Executive acknowledges and agrees that monetary damages for his breach of
any provision of this Agreement would be an inadequate remedy and that would not have an adequate
remedy at law for such breach. Accordingly, Executive

 

 

agrees that, in addition to all other rights and remedies available to the company to enforce its
rights pursuant to this Agreement, Perrigo shall, without the necessity of proving irreparable harm
or of posting a bond, be entitled to such equitable relief from any court with proper jurisdiction,
including, but not limited to, an injunction, a temporary restraining order, or an order for
specific performance, as may be necessary to enforce or prevent a violation (whether anticipatory,
continuing, or future) of any provision of this Agreement. If Executive breaches any provision of
this Agreement, he shall pay all expenses, including court costs and actual attorney fees, incurred
by Perrigo in enforcing such provision.

     6. Enforceability. The unenforceability of any provision or portion of any provision
of this Agreement shall not affect the enforceability of the remaining provisions or the remainder
of any provision of this Agreement. If at any time a court determines that any restrictive covenant
contained in this Agreement is unreasonable, the parties agree that the maximum restriction
permitted by law shall be substituted for the stated restriction and that such substitution shall
govern this Agreement as if originally part of this Agreement.

     7. Binding Effect. This Agreement and the rights and obligations of Perrigo hereunder
shall inure to the benefit of and be binding upon Perrigo and its successors and assigns.

     8. Entire Agreement Modifications. This Agreement contains the entire agreement
between the parties with respect to its subject matter and supersedes all other agreements, whether
oral or written, between the parties regarding such subject matter. This Agreement may be modified
or terminated only through a written instrument signed by each of the parties.

     9. Waiver. The waiver by either party of the enforcement or the breach of any
provision of this Agreement shall not operate or be construed as a subsequent or continuing waiver
of the enforcement or the breach of any provision. The failure by either party to insist upon
strict compliance of any provision of this Agreement shall not be deemed a waiver of such
provision. No waiver shall be valid unless in writing and signed by the party giving the waiver.

     10. Governing Law. This Agreement shall be governed by laws of Israel, provided,
however, that with respect to acts that occur in the United States (“US Based Conduct”) that would
constitute a breach of this Agreement and any disputes relating to such acts shall be governed by
and construed and enforced in accordance with the internal laws of the State of Michigan without
regard to principals of conflict of laws with respect to any acts occurring in the United States.
Any proceeding related to or arising out of this Agreement relating to US Based Conduct shall be
commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand
Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and
in any appellate court thereof. Executive accepts, with respect to US Based Conduct, generally and
unconditionally, the exclusive jurisdiction of the aforesaid

 

 

courts and waives any defense of forum non conveniens, and irrevocably
agrees to be bound by any final and nonappealable judgment rendered thereby in connection with this
Agreement. Executive further irrevocably consents, with respect to US Based Conduct, to the
service of process out of any of the aforementioned courts in any such action or proceeding by the
mailing of copies thereof via overnight courier, such service to become effective fourteen calendar
days after such mailing.

     IN WITNESS WHEREOF, this Agreement been duly executed by the parties as of the day and year first
written above.

PERRIGO COMPANY

	 	 	 	 	 
	By:

	 	/s/ Joseph C. Papa
 

	 	 
	Its:
	 	President and Chief Executive Officer	 	 

EXECUTIVE

	 	 	 	 	 
	By:

	 	/s/ Refael Lebel
 

	 	 
	Executive	 	 

PERRIGO ISRAEL PHARMACEUTICALS LTD.

	 	 	 	 	 
	By:
	 	/s/ Judy L. Brown	 	 
	 

	 	 	 	 
	Its:
	 	Executive Vice President and

Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]